ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bivamelagon

Also written as “Bivamelagon” and “LB54640”.

Its studies are mostly in Sexual Infantilism · Obesity, led by 2 companies.

Drug pageBivamelagon: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Sep 14, 20233 company-led studies, 2 open or runningNext primary completion: Apr 15, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Rhythm Pharmaceuticalsits history only21 open or runningphase 2since Sep 14, 2023Sep 14, 2023Apr 15, 2028phase 2 · NCT07156578
LG Chem11 open or runningphase 2since Sep 11, 2023Sep 11, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of LG Chem only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2023Named bivamelagonINNProposed as its International Nonproprietary Name in WHO's List 129 · before, LB54640
  2. Sep 11, 2023First study: phase 2 study in POMC Deficiency ObesityFirst studyNCT06041841 · 4 planned · France, United Kingdom

TargetBeta

MC4R →read by rule
“An orally bioavailable agonist of melanocortin-4 receptor (MC4R), ”NCIt, by rule

Other programs on MC4R

ProgramCompanyFurthest phaseStudies
setmelanotideruleRhythm Pharmaceuticalsphase 422
bremelanotiderulepalatin-technologies-incphase 48
mifomelatideruleendevica-biophase 22

Studies

The one study LG Chem leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06041841POMC Deficiency Obesity · France, United Kingdom2Not yet recruitingDec 20244

How it is read

Names in the registry

  • “Bivamelagon”, 2 entries
  • “LB54640”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.